Safety review committee releases report on inflammation events due to brolucizumab
- Posted on: Jun 8 2020
- Leave a response
The incidence of retinal vasculitis and retinal vascular occlusion after brolucizumab injections are higher than originally reported, according to a post-hoc review of the phase 3 HAWK and HARRIER trials.
Source: AAO
Posted in: Uncategorized
